Hovione Lumiar

Office and R&D Center

Office and R&D Center

Virtual Tour to our R&D Center in Portugal

 

 

 Hovione's facilities at Lumiar Campus include two buildings:

  • Building R, with three floors, which houses corporate services, namely the areas of Finance, Human Resources, Sales, Marketing & Communication, Regulatory Affairs, among others.
     
  • Building S, also with three floors, where the new Hovione Research and Development Center is located, with a total area of 7,600 m2, equipped with state-of-the-art laboratories and the most advanced technologies in the pharmaceutical industry. About 315 people work in these two buildings, being 220 scientists, 60 of which are PhDs.

These facilities were designed to encourage the sharing of knowledge in a work environment that stimulates teamwork, innovation and creativity.

The buildings’ construction followed the best sustainability practices, using LEED, a green building classification system, resulting in an ecological, efficient building that promotes resource savings and a better environment.

 

For inquiries about Hovione Lumiar, kindly fill the form below.

News

CDMO Hovione and biotechnology company Firstgene Life Sciences (of Xlife Sciences) have collaborated to advance Hovione’s drug delivery platform for the targeted treatment of Hepatocellular Carcinoma (HCC). “We are proud to advance the development of innovative oncology treatments that address a critical unmet need for precision gene expression at the tissue level,” said Hovione CEO Dr Jean-Luc Herbeaux. The virus-like particle technology will be engineered and functionalised for the specific carcinoma cell type using therapeutically validated AAVs, including a novel primer compound. Hovione will be responsible for molecular engineering, the supply of tailor-made virus-like particles and the execution of proof-of-concept studies. “HCC, the most common liver cancer and a leading cause of cancer-related death, continues to represent a major unmet medical need,” said Firstgene managing director Dr Alexander Zink. “The combination of Hovione’s expertise in complex chemistry and particle engineering and the commercialisation expertise of Xlife Sciences positions Firstgene well to offer patients potential new safe and effective therapy options.”   Read the full article at scientistlive.com    

Press Clipping
Scientist Live, 12 May 2025

Partnership advances liver cancer treatment

May 12, 2025

CDMO Hovione and biotechnology company Firstgene Life Sciences (of Xlife Sciences) have collaborated to advance Hovione’s drug delivery platform for the targeted treatment of Hepatocellular Carcinoma (HCC). “We are proud to advance the development of innovative oncology treatments that address a critical unmet need for precision gene expression at the tissue level,” said Hovione CEO Dr Jean-Luc Herbeaux. The virus-like particle technology will be engineered and functionalised for the specific carcinoma cell type using therapeutically validated AAVs, including a novel primer compound. Hovione will be responsible for molecular engineering, the supply of tailor-made virus-like particles and the execution of proof-of-concept studies. “HCC, the most common liver cancer and a leading cause of cancer-related death, continues to represent a major unmet medical need,” said Firstgene managing director Dr Alexander Zink. “The combination of Hovione’s expertise in complex chemistry and particle engineering and the commercialisation expertise of Xlife Sciences positions Firstgene well to offer patients potential new safe and effective therapy options.”   Read the full article at scientistlive.com    

Press Clipping
Scientist Live, 12 May 2025

Partnership advances liver cancer treatment

May 12, 2025

Dear Customer, As you may be aware, Portugal and Spain experienced yesterday, April 28 (at approximately 11:30) a widespread power outage. This unexpected event, beyond our control, affected the normal activities at our sites in Portugal. In response, we promptly activated our contingency protocols for this type of situation, prioritizing the safety of facilities and personnel. All ongoing processes were taken to safe hold points, and no new processes were initiated. Our backup power generators ensured continuity of critical functions throughout the duration of the outage, which lasted approximately 11 hours, until the power from the grid was restored at the site. The site began resuming operations gradually through the night making sure all systems being restarted safely and verified to be in good working conditions. We anticipate that most activities will be fully resumed during today. Should you have any specific questions regarding your product or project, we kindly encourage you to contact your Account Manager or Project Manager, who will be glad to assist you. We sincerely appreciate your understanding and continued partnership.      

News
News release, 29 April 2025

Widespread power outage in Portugal - Message to our clients

Apr 29, 2025

Events

Office and R&D Center
Address

Hovione Farmaciência S.A.
Estrada do Paço do Lumiar,
Campus do Lumiar, Edifício R
1649-038 Lisboa
Portugal
Tel: +351 21 982 9000
Fax: +351 21 982 9388
E-mail: contact@hovione.com
DUNS Number: 338285630
Location: 38°46'21.72" N     -9°10'49.1874" W

Other Locations

Hovione India

Office
Address

Hovione Holding Limited
C/o WeWork, 2nd floor,
Oberoi Commerz - II,  1,
Off Western Express Highway,
Oberoi Garden City, Goregaon East, Mumbai, Maharashtra 400063
India
Tel.: +919 004 261 523

View all details